<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978884</url>
  </required_header>
  <id_info>
    <org_study_id>ECP231516</org_study_id>
    <nct_id>NCT03978884</nct_id>
  </id_info>
  <brief_title>Phase 4 Study of the Efficacy of Losartan Based Therapy in Hypertensives With and Without Diabetes</brief_title>
  <official_title>An Open Label, Single Arm Prospective Study to Evaluate Efficacy and Safety of Losartan Based Therapy Reslio® (Losartan) and Resilo-h® (Losartan+Hydrochlorthiazide) in Diabetic and Uncontrolled Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of The West Indies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Caribbean College of Family Physicians</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of The West Indies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study antihypertensive efficacy of 12 weeks of Losartan based therapy Resilo (Losartan)&#xD;
      and Resilo-H (Losartan+ Hydrochlorothiazide) in uncontrolled hypertensive and diabetic&#xD;
      hypertensive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 hundred Subjects will be treated with a dose escalation regimen to achieve a target blood&#xD;
      pressure. Subjects with mild hypertension at baseline will be started with losartan 50 mgs&#xD;
      and those with severe hypertension will be started with losartan H 100/25. After 6 weeks they&#xD;
      will titrated if goal blood pressure not achieved. For Mild hypertensive group this will be&#xD;
      with losartan H 100/25 and for severe hypertensive group this will by addition of amlodipine&#xD;
      5 mg to regime. Subjects with mild hypertension and diabetes at baseline will be started with&#xD;
      losartan H 50/12.5 mg and those with severe hypertension with diabetes will be started with&#xD;
      losartan H 100/25. After 6 weeks they will be titrated if goal blood pressure not achieved.&#xD;
      For Mild hypertensive-diabetic group this will be with Resilo H 100/25 and for severe&#xD;
      hypertensive group this will by addition of amlodipine 5 mg to regime.&#xD;
&#xD;
      Target Blood Pressure is systolic &lt; 140 mmhg and diastolic &lt; 90 mmHg if age &lt; 60 years and&#xD;
      systolic &lt; 150 mmHg and diastolic &lt; 90 mmHg if age &gt;60 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to effective arrange trial logistics&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects achieving Target Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Mild Hypertensive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild Hypertensive with systolic BP &gt;=140 mmHg but less than 160 mmHg at baseline with diastolic &gt;=90 but &lt;100 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hypertensive with Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild Hypertensive with systolic BP &gt;=140 mmHg but less than 160 mmHg at baseline with diastolic &gt;=90 but &lt;100 mmHg and diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Hypertensive with systolic BP &gt;=160 mmHg at baseline or with diastolic &gt;=100 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hypertension with Diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Hypertensive with systolic BP &gt;=160 mmHg at baseline or with diastolic &gt;=100 mmHg with diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan 50Mg Tab</intervention_name>
    <description>Take 1 tab daily</description>
    <arm_group_label>Mild Hypertensive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET</intervention_name>
    <description>Take 1 tab daily</description>
    <arm_group_label>Mild Hypertensive with Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET</intervention_name>
    <description>Take 1 tab daily</description>
    <arm_group_label>Mild Hypertensive</arm_group_label>
    <arm_group_label>Mild Hypertensive with Diabetes</arm_group_label>
    <arm_group_label>Severe Hypertension</arm_group_label>
    <arm_group_label>Severe Hypertension with Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 5mg</intervention_name>
    <description>Take 1 tablet daily</description>
    <arm_group_label>Severe Hypertension</arm_group_label>
    <arm_group_label>Severe Hypertension with Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to sign Informed Consent Form.&#xD;
&#xD;
          -  Patients of either sex above 18 years of age.&#xD;
&#xD;
          -  Patients not previously diagnosed with hypertension and with sitting blood pressure &gt;&#xD;
             140/90 mmHg on two readings 15 minutes apart.&#xD;
&#xD;
          -  Newly diagnosed hypertensive patients.&#xD;
&#xD;
          -  Hypertensive patients on other antihypertensive therapies but not at goal&#xD;
&#xD;
          -  Diabetes defined as patient on insulin therapy or oral diabetic therapy or fasting&#xD;
             blood glucose on screening &gt; 7 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of allergic reaction to any angiotensin II antagonist or a&#xD;
             thiazide diuretic&#xD;
&#xD;
          -  Patients with history suggestive secondary hypertension&#xD;
&#xD;
          -  Patients who have taken Resilo or Resilo-H or other losartan based treatment in past&#xD;
             three months of study inclusion.&#xD;
&#xD;
          -  Patients with chronic renal failure or who on screening has serum creatinine &gt;150&#xD;
             µmol/L&#xD;
&#xD;
          -  Patients who is participating concurrently in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>self-representation of gender identity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin Reid</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the West Indies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tropical Metabolism Research Unit</name>
      <address>
        <city>Kingston</city>
        <state>Other</state>
        <zip>007</zip>
        <country>Jamaica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jamaica</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

